- Home
- PHAR vs CRGX Comparison
PHAR vs CRGX Comparison
Compare PHAR & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CRGX
- Stock Information
- Founded
- PHAR 1988
- CRGX 2021
- Country
- PHAR Netherlands
- CRGX United States
- Employees
- PHAR N/A
- CRGX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- PHAR Health Care
- CRGX
- Exchange
- PHAR Nasdaq
- CRGX Nasdaq
- Market Cap
- PHAR 731.1M
- CRGX 190.0M
- IPO Year
- PHAR N/A
- CRGX 2023
- Fundamental
- Price
- PHAR $10.00
- CRGX $4.59
- Analyst Decision
- PHAR Strong Buy
- CRGX Hold
- Analyst Count
- PHAR 3
- CRGX 7
- Target Price
- PHAR $30.00
- CRGX $5.33
- AVG Volume (30 Days)
- PHAR 3.6K
- CRGX 1.9M
- Earning Date
- PHAR 07-31-2025
- CRGX 08-11-2025
- Dividend Yield
- PHAR N/A
- CRGX N/A
- EPS Growth
- PHAR N/A
- CRGX N/A
- EPS
- PHAR N/A
- CRGX N/A
- Revenue
- PHAR $320,708,000.00
- CRGX N/A
- Revenue This Year
- PHAR $13.31
- CRGX $57.81
- Revenue Next Year
- PHAR $7.68
- CRGX N/A
- P/E Ratio
- PHAR N/A
- CRGX N/A
- Revenue Growth
- PHAR 24.13
- CRGX N/A
- 52 Week Low
- PHAR $6.65
- CRGX $3.00
- 52 Week High
- PHAR $12.61
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- CRGX 61.56
- Support Level
- PHAR $9.99
- CRGX $4.32
- Resistance Level
- PHAR $10.59
- CRGX $4.63
- Average True Range (ATR)
- PHAR 0.35
- CRGX 0.16
- MACD
- PHAR -0.14
- CRGX 0.04
- Stochastic Oscillator
- PHAR 7.45
- CRGX 76.44
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.